CD33 positivity and MPC-1 negativity appear to be associated with worse outcomes in patients with multiple myeloma treated with bortezomib as induction therapy. A CAR-T therapy for myeloma that is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results